Aims: To introduce delegates to the biology, diagnosis, staging, and treatments of cancer and how these relate tot he main outcome measures used in cancer clinical trials (adverse events, response, survival and other time to event endpoints).
The course will provide delegates an excellent opportunity to network with statisticians from other UKCRC registered clinical trial units.
Target Audience: This is an introductory course suitable for recent MSc graduates or more experienced statisticians new to the field of cancer treatment trials.
Delegates do not need to have prior knowledge of cancer.
Learning Outcomes: At the end of the course participants should have greater knowledge of the date that contribute to cancer clinical trial reports and approaches to the appropriate analysis/presentation of such data, specifically:
- Cancer biology and how this impacts on choice of treatment, tumour spread and outcome measures
- Cancer diagnosis and staging and how these impact on pre-trial entry screening tests and eligibility criteria
- Commonly reported patients and tumour characteristics and issues in choosing appropriate stratification factors
- Cancer treatments and issues in reporting protocol compliance
- Adverse events due to cancer therapies and reporting these events
- Response criteria in solid and non solid tumours and reporting response endpoints
- Issues in survival and time to event analyses
- The challenges of trials including novel targeted agent therapy.